The HIV PrEP and Microbicides Pipeline
Pipeline • 2018July 2018 by Jeremiah Johnson Since 2011, HIV prevention has undergone a true revolution. With three major studies (HPTN 052, PARTNER, and Opposites Attract) now showing zero new infections linked to an HIV positive person who has successfully suppressed their virus through antiretroviral treatment, it is now apparent that being “undetectable” means that a person…
The TB CAB and TAG Welcome WHO Recommendation of Injectable-Free Regimens for the Treatment of RR/MDR-TB
Statement / Press • 2018The Global Tuberculosis Community Advisory Board (TB CAB) and Treatment Action Group (TAG) welcome the new World Health Organization (WHO) recommendation of injectable-free regimens for the treatment of rifampicin- and multidrug-resistant tuberculosis (RR/MDR-TB).
Letter from Health Organizations: NAFTA Renegotiations Must Not Undermine Access to Affordable Medicines
Letters • 2018A group of 97 International, U.S., Canadian, and Mexican health organizations sent this letter to representatives of those countries, asking them to ensure that any North American Free Trade Agreement (NAFTA) renegotiations don’t undermine access to affordable medicines.
TAG Urges Action to Oppose Trump’s HHS Pick
Statement / Press • 2017TAG Statement for the Record in Opposition to the Nomination of Tom Price for HHS Secretary
Sign-on Letter in Response to Critical Shortage of Penicillin for Syphilis Treatment in U.S.
Letters • 2017Sign-on letter to Pfizer urging an immediate response to the nationwide shortage of pencillin G benzathine, the standard treatment for primary and secondary syphyilis. Community Calls On United Healthcare to End Discriminatory Prior Authorization Practices for PrEP Access
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
Statement / Press • 2017Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs
Statement / Press • 2017With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.
Viekira XR and Technivie Fact Sheet
Publication • 2017Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination of hepatitis C virus–fighting drugs (paritaprevir/ritonavir/ombitasvir and dasabuvir) that block different steps of the virus…
Universal Health Care and Prescription Drug Pricing
TAGline • 2017Reining in prescription drug prices isn’t so much a potential benefit of universal health care, but rather a factor in its affordability and success By Tim Horn If there is one thing the majority of Americans agree on, it’s that health care costs—prescription drugs, in particular—are out of control and are significantly contributing to our…
Introduction and Executive Summary
Pipeline • 2017July 2017 By Mark Harrington INTRODUCTION This year marks the 30th year since the U.S. Food and Drug Administration (FDA) granted a license for Burroughs-Wellcome to market AZT (zidovudine, Retrovir), the first approved drug to treat HIV infection, at the then-unprecedented price of $10,000 per year. The hope instigated by this apparent medical progress mixed…